Trump Media Reports First Quarter 2025 Results

3 days ago

~ Ended First Quarter with $759.0 Million in Cash/Investments ~ ~ Operations Consumed Just $9.7 million of Cash Despite $10.9…

Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases

3 days ago

New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following…

Arabella Advisors Names Mark Loch As Head of Redstone Consulting

3 days ago

Loch to lead firm’s consulting practice across Arabella Advisors and Redstone Strategy GroupWashington, DC, May 09, 2025 (GLOBE NEWSWIRE) --…

Party Go Round Expands Its Fun-Filled Event Services to Cincinnati

3 days ago

A trusted provider of inflatable party rentals brings its popular bounce houses and more to the Queen City in Cincinnati.…

Camfil USA Clean Air Blog Updates – Critical Insights on Indoor Air Quality Challenges

3 days ago

The revamped content initiative arrives as organizations nationwide confront increasing concerns about air quality impacts on health, productivity, and operational…

Volcon ePowersports Reports Operational Highlights and First Quarter 2025 Financial Results

3 days ago

AUSTIN, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Volcon Inc. (NASDAQ: VLCN) (“Volcon'', the “Company” or “we”), the first all-electric,…

NI Holdings, Inc. Reports Results for First Quarter Ended March 31, 2025

3 days ago

FARGO, N.D., May 09, 2025 (GLOBE NEWSWIRE) -- NI Holdings, Inc. (NASDAQ: NODK) announced today results for the quarter ended…

Motorsport Games Reports First Quarter 2025 Financial Results

3 days ago

Motorsport Games Reports First Quarter 2025 Financial Results Financial results for Q1 2025 for Motorsport Games (NASDAQ:MSGM) have been published.…

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

3 days ago

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology…

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

3 days ago

        - Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more…

This website uses cookies.